Overview
Sponsor-declared trial summary
Phase
Human pharmacology (Phase I) - Other
Status
Authorised, recruitment pending
Participants planned
20
Countries
1
Sites
1
Chronic Heart Failure
Key facts
- Sponsor
- Corteria Pharmaceuticals
- Participant type
- Healthy volunteers
- Age range
- 18-64 years, 65+ years
- Gender
- Male and Female
- Therapeutic area
- Diseases [C] - Cardiovascular Diseases [C14]
- Decision date (initial)
- 2026-05-13
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- No
Trial design
CTIS Part I — objectives, methods, condition coding
Conditions and MedDRA coding
Chronic Heart Failure
| Version | Level | Code | Term | System organ class |
|---|---|---|---|---|
| 20.0 | LLT | 10008908 | Chronic heart failure | 10007541 |
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Corteria Pharmaceuticals
- Sponsor organisation
- Corteria Pharmaceuticals
- Address
- 128 Rue La Boetie
- City
- Paris
- Postcode
- 75008
- Country
- France
Scientific contact point
- Organisation
- Corteria Pharmaceuticals
- Contact name
- Chief Medical Officer - Francesca Lawson
Public contact point
- Organisation
- Corteria Pharmaceuticals
- Contact name
- Chief Medical Officer - Francesca Lawson
Locations
1 EU/EEA country · 1 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Netherlands | Authorised, recruitment pending | 20 | 1 |
| Rest of world | — | 0 | — |
Investigational sites
Pharmaceutical Research Associates Group B.V.
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen
Application history
1 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2026-03-27 | Netherlands | Acceptable 2026-05-13
|
2026-05-13 |